Moteur de recherche d’entreprises européennes

Financement de l’UE (11 M €) : Évaluation à distance de la maladie et de la rechute dans les troubles du système nerveux central Hor01/04/2016 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Évaluation à distance de la maladie et de la rechute dans les troubles du système nerveux central

Background: Long term conditions require monitoring of patients, traditionally conducted in the clinic, to monitor treatment effects, adverse events and disease course. This can be inefficient and cumbersome – clinic visits may be too infrequent to identify individuals at risk of significant changes in disease state (e.g. relapse) and place unnecessary burden on patients and providers. Smartphone and wearable technologies have led to an exponential growth in the amount of information which can be collected on patients unobtrusively and at low cost. Sensors collect data passively, and active monitoring, using experience sampling, provides information on multiple parameters. Such technologies could monitor long term outcomes of patients, at scale, and provide fine-grained information on outcomes, available in real time and at low-cost, enabling services to offer more responsive and efficient care. Whilst there is growing interest in the application of RMT in health, the field is in its infancy. The private-public partnership fostered by IMI2 is an ideal way to overcome the inherent challenges of this field. Our ultimate goal is to improve patient outcomes through remote assessment. To achieve this we will create a pipeline for developing, testing and implementing RMT in depression, multiple sclerosis and epilepsy. The pipeline will include a data management and modelling infrastructure applicable to other disorders and with the flexibility of design to be future-proofed against further technological innovation. We will provide data on implementation barriers and facilitators gleaned from patients, clinicians, regulator and payers which will optimise the pathways for regulatory approval and uptake. Program of Work: In order to test the feasibility and predictive power of RMT four main components are required: (1) Excellent project oversight, management, and a dissemination and exploitation strategy;


Biogen Idec Ltd. 0,00 €
Charite - Universitaetsmedizin Berlin 62 500 €
Consorcio Centro de Investigacion Biomedica en Red M.P 674 981 €
Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca 427 235 €
Fundacio Privada Per A La Recerca i La Docencia Sant Joan de Deu 0,00 €
Gabo:MI Gesellschaft FUR Ablauforganisation:Milliarium mbH & Co. KG 23 076 €
H. Lundbeck AS 0,00 €
Intel Corporation (UK) Ltd. 0,00 €
Janssen Pharmaceutica N.V. 0,00 €
Katholieke Universiteit Leuven 526 000 €
King's College London 4 078 267 €
MSD Czech Republic s.r.o. 0,00 €
Northwestern University Corporation 0,00 €
Ospedale SAN Raffaele Srl 0,00 €
Provincia Lombardo Veneta - Ordineospedaliero Di SAN Giovanni Di DIO- Fatebenefratelli 180 000 €
Region Hovedstaden 405 000 €
Software AG 0,00 €
Stichting Amsterdam UMC 488 000 €
Stichting Imec Nederland 111 000 €
Stichting Lygature 1 345 961 €
THE Hyve B.V. 0,00 €
The University of Nottingham 625 000 €
UCB Biopharma 0,00 €
Universita' Degli Studi Di Bergamo 125 000 €
Universitaet Augsburg 433 648 €
Universitaetsklinikum Freiburg 825 000 €
Universitat Passau 116 352 €
Universita Vita-Salute SAN Raffaele 552 980 €

https://cordis.europa.eu/project/id/115902

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.